The clinical diagnostic value of plasma miR-592 and miR-217-3p levels in retinoblastoma

  • JinYan Luo Nanchang Hongdu Hospital of Traditional Chinese Medicine
  • BinLin Huang Jiangxi University of Traditional Chinese Medicine
  • QiYu Hu Nanchang Hongdu Hospital of Traditional Chinese Medicine
  • RuJie Li Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
  • Jun Chen Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
  • LingMei Yuan Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
  • Yuan Peng Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
DOI: https://doi.org/10.5937/jomb0-34794
Keywords: retinoblastoma, miR-592, miR-217-3p, correlation

Abstract


Background: This study was designed to investigate the abnormal expression of plasma miR-592 and miR-217-3p in retinoblastoma (Rb) and explore the clinical diagnostic value of their expression levels for Rb. Methods: The 100 Rb patients who came to Nanchang Hongdu Hospital of Traditional Chinese Medicine from January 2018 to January 2019 were selected as the Rb group, and 100 healthy patients who came to the physical examination centre during the same period were selected as the control group. Real-time fluorescence quantitative PCR (qRT-PCR) was used to detect the expression levels of plasma miR-592 and miR-217-3p in all subjects; analyse the relationship between plasma miR-592 and miR-217-3p levels and the clinicopathological characteristics of Rb. Pearson correlation analysis evaluated the relationship between plasma miR-592 and miR-217-3p levels and overall survival. Results: Plasma levels of miR-592 and miR-217-3p in the Rb group were significantly higher than those in the control group (p<0.0001), and the expression of miR-592 was significantly correlated with family genetic history (p 0.0001), tumour bias (p=0.0081), lymph node metastasis (p=0.0048) and pathological grade (p=0.0025), and the expression of miR-217-3p was significantly related to family genetic history (p 0.0001), optic nerve infiltration (p 0.0001), lymph node metastasis (p=0.0090), and pathological grade (p 0.0001). The high expression of miR-592 and miR-217-3p presents a more serious pathological manifestation of Rb, and the overall survival of patients is significantly shortened with the increase of miR-592 (r=0.2276, p=0.0052) and miR-217-3p levels (r=-0.6461, p 0.0001). Conclusions: and miR-217-3p are highly expressed in the plasma of Rb patients, and their elevated levels present severe pathological manifestations of Rb and shortened overall survival, which is expected to become biomarkers for clinical diagnosis of Rb. 

References

1. Zhou, W., et al., Weighted genes associated with the progression of retinoblastoma: Evidence from bioinformatic analysis. Exp Eye Res, 2021. 211: p. 108730.
2. Rajasekaran, S., et al., Integrated multi-omics analysis of RB-loss identifies widespread cellular programming and synthetic weaknesses. Commun Biol, 2021. 4(1): p. 977.
3. Zhao, J., Z. Feng, and B.L. Gallie, Natural History of Untreated Retinoblastoma. Cancers (Basel), 2021. 13(15).
4. Tomar, A.S., et al., Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging. Br J Ophthalmol, 2021.
5. Gupta, H., et al., Retinoblastoma genetics screening and clinical management. BMC Med Genomics, 2021. 14(1): p. 188.
6. Gu, H., et al., Clinical features and imaging manifestations of retinoblastoma with hepatic metastasis. Pediatr Blood Cancer, 2021. 68(10): p. e28959.
7. Martinez-Sanchez, M., et al., Retinoblastoma: from discovery to clinical management. FEBS J, 2021.
8. Manrique, M., et al., Update on the Treatment of Retinoblastoma. Neoreviews, 2021. 22(7): p. e423-e437.
9. Xie, Y., X.L. Xu, and W.B. Wei, The RB1 Mutation Spectrum and Genetic Management Consultation in Pediatric Patients with Retinoblastoma in Beijing, China. Risk Manag Healthc Policy, 2021. 14: p. 3453-3463.
10. Al Qahtani, M., S. AlMasfer, and R. Khandekar, Health related quality of life of patients treated with bilateral enucleation for retinoblastoma. Eur J Ophthalmol, 2021: p. 11206721211035637.
11. Jakati, S., et al., Lenticular changes in eyes with advanced intraocular retinoblastoma: A histopathological study of 48 enucleated eyes. Semin Ophthalmol, 2021: p. 1-5.
12. Fang, X., et al., RB1 germline mutation spectrum and clinical features in patients with unilateral retinoblastomas. Ophthalmic Genet, 2021. 42(5): p. 593-599.
13. Long, K., et al., Green Light-Triggered Intraocular Drug Release for Intravenous Chemotherapy of Retinoblastoma. Adv Sci (Weinh), 2021: p. e2101754.
14. Gu, X., et al., Publication Trends of Research on Retinoblastoma During 2001-2021: A 20-Year Bibliometric Analysis. Front Med (Lausanne), 2021. 8: p. 675703.
15. Mendonca, V., et al., Molecular alterations in retinoblastoma beyond RB1. Exp Eye Res, 2021. 211: p. 108753.
16. Lande, K., et al., Exosomes: Insights from Retinoblastoma and Other Eye Cancers. Int J Mol Sci, 2020. 21(19).
17. Yu, W.L., S. Liang, and C.Z. Zhang, Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma. Neuromolecular Medicine, 2018. 20(4): p. 452-474.
18. Delsin, L.E.A., et al., Expression profiles and prognostic value of miRNAs in retinoblastoma. J Cancer Res Clin Oncol, 2019. 145(1): p. 1-10.
19. Castro-Magdonel, B.E., et al., miRNome landscape analysis reveals a 30 miRNA core in retinoblastoma. Bmc Cancer, 2017. 17.
20. Zhao, X.M., et al., Bioinformatics analysis of key biomarkers for retinoblastoma. J Int Med Res, 2021. 49(6): p. 3000605211022210.
21. Zhao, Y., et al., lncRNA MALAT1 regulated ATAD2 to facilitate retinoblastoma progression via miR-655-3p. Open Med (Wars), 2021. 16(1): p. 931-943.
22. Zhu, Y. and F. Hao, Knockdown of long noncoding RNA HCP5 suppresses the malignant behavior of retinoblastoma by sponging miR36195p to target HDAC9. Int J Mol Med, 2021. 47(5).
23. Miyamoto, M., et al., Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells. Sci Rep, 2020. 10(1): p. 16755.
24. Kivela, T.T. and T. Hadjistilianou, Neonatal Retinoblastoma. Asia Pac J Oncol Nurs, 2017. 4(3): p. 197-204.
25. van Hoefen Wijsard, M., et al., Benign Tumors in Long-Term Survivors of Retinoblastoma. Cancers (Basel), 2021. 13(8).
26. Gui, T., et al., Clinical and magnetic resonance imaging features of 14 patients with trilateral retinoblastoma. Quant Imaging Med Surg, 2021. 11(4): p. 1458-1469.
27. Dhingra, H., et al., A study analyzing the health-related quality of life of retinoblastoma survivors in India. Indian J Ophthalmol, 2021. 69(6): p. 1482-1486.
28. Fabius, A.W.M., et al., Subsequent Malignant Neoplasms in Retinoblastoma Survivors. Cancers (Basel), 2021. 13(6).
29. Selvarajah, A., et al., Clinical audit of retinoblastoma management: a retrospective single-institution study. Can J Ophthalmol, 2021.
30. Lal, P., Role of radiotherapy in retinoblastoma. Indian J Ophthalmol, 2021. 69(10): p. 2912-2913.
31. Fang, X., et al., Clinical Features of Children with Retinoblastoma and Neuroblastoma. J Ophthalmol, 2020. 2020: p. 9315784.
32. Luo, Y., et al., Contemporary update of retinoblastoma in China: Three-decade changes in epidemiology, clinical features, treatments and outcomes. Am J Ophthalmol, 2021.
33. Vempuluru, V.S. and S. Kaliki, Screening for Retinoblastoma: A Systematic Review of Current Strategies. Asia Pac J Ophthalmol (Phila), 2021. 10(2): p. 192-199.
34. Mirzayev, I., et al., The Final Diagnosis: Retinoblastoma or Pseudoretinoblastoma. J Pediatr Ophthalmol Strabismus, 2021. 58(3): p. 161-167.
35. Jiang, H.G., et al., Four plasma miRNAs act as biomarkers for diagnosis and prognosis of non-small cell lung cancer. Oncology Letters, 2021. 22(5).
36. Maries, L., et al., MicroRNAs-The Heart of Post-Myocardial Infarction Remodeling. Diagnostics (Basel), 2021. 11(9).
37. Nooh, M., et al., Prediction of Blood miRNA-mRNA Regulatory Network in Gastric Cancer. Rep Biochem Mol Biol, 2021. 10(2): p. 243-256.
38. Liu, J., et al., Development of a two-circular RNA panel as potential prognostic biomarker for gastric cancer. Journal of Translational Medicine, 2021. 19(1).
39. Bereimipour, A., L. Satarian, and S. Taleahmad, Investigation of Key Signaling Pathways Associating miR-204 and Common Retinopathies. Biomed Res Int, 2021. 2021: p. 5568113.
40. Wu, A., et al., LINC00202 promotes retinoblastoma progression by regulating cell proliferation, apoptosis, and aerobic glycolysis through miR-204-5p/HMGCR axis. Open Life Sci, 2020. 15(1): p. 437-448.
41. Ding, J. and X. Lu, Expression of miR-204 in pediatric retinoblastoma and its effects on proliferation and apoptosis of cancer cells. Oncol Lett, 2018. 16(6): p. 7152-7157.
42. Zhou, P. and X.M. Li, Serum miR-338-5p has potential for use as a tumor marker for retinoblastoma. Oncology Letters, 2019. 18(1): p. 307-313.
43. Xu, L., et al., LncRNA MBLN1-AS1 inhibits the progression of retinoblastoma through targeting miR-338-5p-Wnt/beta-catenin signaling pathway. Inflamm Res, 2021. 70(2): p. 217-227.
44. Pan, Z.G. and L. Miao, Serum microRNA-592 serves as a novel potential biomarker for early diagnosis of colorectal cancer. Oncology Letters, 2020. 20(2): p. 1119-1126.
45. Liu, M.L., et al., Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer. Biomedicine & Pharmacotherapy, 2015. 69: p. 214-220.
46. Martinez-Gonzalez, L.J., et al., Identification of MicroRNAs as Viable Aggressiveness Biomarkers for Prostate Cancer. Biomedicines, 2021. 9(6).
47. Lv, Z., P. Rao, and W. Li, MiR-592 represses FOXO3 expression and promotes the proliferation of prostate cancer cells. Int J Clin Exp Med, 2015. 8(9): p. 15246-53.
48. Liu, Z., et al., MiR-592 inhibited cell proliferation of human colorectal cancer cells by suppressing of CCND3 expression. Int J Clin Exp Med, 2015. 8(3): p. 3490-7.
49. Pan, Z.G., et al., MicroRNA-592 promotes cell proliferation, migration and invasion in colorectal cancer by directly targeting SPARC. Molecular Medicine Reports, 2021. 23(4).
50. Tang, X.F., et al., LncRNA HOTAIR Contributes to Sorafenib Resistance through Suppressing miR-217 in Hepatic Carcinoma. Biomed Research International, 2020. 2020.
51. Wang, H., et al., Long non-coding RNA CRNDE promotes the proliferation, migration and invasion of hepatocellular carcinoma cells through miR-217/MAPK1 axis. J Cell Mol Med, 2018. 22(12): p. 5862-5876.
Published
2022/03/16
Issue
Vol. 41 No. 4 (2022): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2022 BinLin Huang, JinYan Luo, QiYu Hu, RuJie Li, Jun Chen, LingMei Yuan, Yuan Peng

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.